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Introduction
Polycystic liver disease (PLD) is a rare hereditary 
disorder characterized by the formation of multi-
ple cysts in the liver. Development of liver cysts is 
the primary presentation in patients with autoso-
mal dominant polycystic liver disease (ADPLD), 
and the most frequent extra-renal manifestation 
in patients with autosomal dominant polycystic 
kidney disease (ADPKD).1 PC-1 deficiency, 
caused by genetic mutations, plays a defining role 
in liver cystogenesis. It leads to decreased intra-
cellular calcium levels, cAMP activation and sub-
sequent cell proliferation and fluid production.2 
Although the majority of PLD patients remain 
without symptoms, patients with severe hepato-
megaly could develop severe mechanical symp-
toms and malnutrition. This category of patients 
is in need of treatment.3
A growing body of evidence suggests that somato-
statin analogues (SAs) possess a liver volume-
reducing effect and alter the natural growth of the 
polycystic liver. SAs reduce cell proliferation and 
fluid production by inhibiting cAMP production 
in cholangiocytes.4 In a pooled analysis from 
three randomized controlled trials, livers from 
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Background: Somatostatin analogues (SAs) reduce liver volume and relief symptoms 
in polycystic liver disease (PLD). Its effect wears off after continuing therapy suggesting 
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patients on placebo grew by 1.8% whereas SAs 
for 6–12 months gave a decrease of 3.6%.5–8 
Withdrawal of treatment led to a recurrence of 
the growth rate to values seen at the baseline.9,10
A study suggests that chronic SA therapy for symp-
tomatic patients is warranted based on results of a 
placebo-controlled single-blind trial in which 
patients were successfully treated with SAs for 
3 years.10 However, the results of this study cannot 
be translated to all PLD patients and there are a 
number of potential issues that preclude wide-
spread use of chronic SA therapy. One of the main 
issues is that the effect of the drug is mainly 
achieved in the first months of treatment and wears 
off beyond that.9 This suggests that tolerance to 
SAs develops in patients on chronic therapy. Drug 
holidays, defined as an interruption of pharmaco-
therapy for a defined period of time, could be the 
answer to prevent the development of tolerance. 
Indeed, drug holidays have been hypothesized to 
‘resensitize the system’ to the acute pharmacologi-
cal effects for other types of drug.11,12 For instance, 
retreatment with chemotherapy is an established 
practice in many cancers such as lung cancer, gas-
trointestinal stromal tumours (GISTs) and renal 
cell cancer.13,14 Although PLD is a benign disease, 
we reasoned that rechallenge after a drug holiday 
might benefit PLD patients.
We examined the effect of SA rechallenge after a 
drug holiday and explored whether the benefit 
from treatment is related to the initial response to 
treatment, and whether the length of drug holiday 
affects treatment success. In addition, we compare 
natural growth before the start and after cessation 
of SA therapy to determine a rebound effect.
Methods
Patients and study design
The International PLD Registry, which consists 
of PLD patients with >10 liver cysts, allows us to 
explore these issues in a real-world cohort in 
which clinical data from individual patients are 
collected uniformly.15,16 Patients from two cent-
ers [Radboud University Medical Center 
(Nijmegen, The Netherlands) and University 
Hospital Leuven (Leuven, Belgium)] were evalu-
ated for inclusion since these were the only cent-
ers with a history of SA prescription. Out of 741 
patients, included in the International PLD 
Registry until December 2017, 231 patients were 
treated with SAs at least once. Selection for our 
study was based on the following inclusion crite-
ria: (1) SA therapy-naïve PLD patients treated 
with any type of SA for two separate cycles with a 
drug holiday in between; (2) each cycle (either 
treatment or drug holiday) lasted at least 3 
months; (3) minimum interval between consecu-
tive imaging was 3 months; and (4) height-
adjusted liver volume (hTLV) was available at the 
start and end of each cycle (either treatment or 
drug holiday) and measured with computed 
tomography (CT) or magnetic resonance imaging 
(MRI). Selected patients were treated with SAs in 
regular clinical care or they participated in pro-
spective clinical trials.6,9,17–19 All imaging in clini-
cal trials and regular clinical care was performed 
according to standard protocols. The majority of 
patients received lanreotide 120 mg subcutane-
ously or octreotide 40 mg intramuscular every 
28 days. In some patients, dose escalation 
occurred, especially in the second treatment cycle 
(Table S2, supplementary files).
For our primary research question, we compared 
the effect of SAs on hTLV in two treatment cycles 
(On-1 versus On-2) separated by a drug holiday 
(Off-1) to evaluate whether the volume-reducing 
effect of SAs is repeated. For our secondary 
research question, we aimed to compare natural 
liver growth before SA treatment (Off-0) with liver 
volume change during drug holiday (Off-0 versus 
Off-1) to evaluate whether a rebound effect occurs. 
Therefore, we included all patients in whom hTLV 
was available before the start of the first treatment 
cycle. Figure 1 illustrates the design of our study.
For both research questions we excluded patients 
in case imaging was performed >2 months after 
Figure 1. Study design.
BOT-1, imaging at beginning of first treatment period; BOT-
2, imaging at beginning of second treatment period; EOT-1, 
imaging at end of first treatment period; EOT-2, imaging at 
end of second treatment period; NOT-0, imaging prior to SA 
treatment; Off-0, drug-free period prior to SA treatment; 
Off-1, drug-free period between two SA periods; On-1, first 
treatment period; On-2, second treatment period.
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the start or end of SA therapy as this might under-
estimate the effect of SAs and the natural growth 
in the preceding drug-free period. Patients were 
also excluded who received other liver volume-
reducing therapy during our observation period.
Data collection
The following data were extracted from the 
International PLD Registry; sex, age, height, 
weight, body mass index (BMI), etiology 
(ADPKD/ADPLD), date and type of imaging 
(CT/MRI), liver volume, treatment (type, dose 
and duration of treatment) and serious adverse 
events (SAEs). Liver volume was measured in 
the past as part of clinical trials or regular clinical 
care by assessing CT or MRI imaging using semi-
automatic software; CT scans in Belgium were 
measured with Volume (Siemens, Erlangen, 
Germany)18,20 and in the Netherlands with 
Pinnacle3® version 8.0 (Philips, Eindhoven, The 
Netherlands).21,22 Volumetry on MRI was per-
formed with Analyze 11 software (AnalyzeDirect 
Inc).23 Liver volume was divided by height to 
obtain hTLV.
Ethical consideration
Concerning ethical approval of the International 
PLD Registry and thereby these analyses, for-
mal evaluation was waived by the Institute 
Review Board Committee on Research 
Involving Human Subjects Arnhem-Nijmegen 
given the retrospective character of the data 
collection in the PLD Registry. Ethical approval 
has been obtained for all clinical trials in which 
these patients participated in the past. This 
study was conducted in accordance with good 
clinical practice guidelines and the code of con-
duct for medical research (www.federa.org). 
No identifying patient data were collected, and 
all patient data were anonymously entered in 
the database.
Statistical analyses
Baseline characteristics were presented as mean 
[standard deviation (SD)] for normally distrib-
uted data, median [interquartile range (IQR)] for 
nonnormally distributed data and absolute num-
bers with percentages (%) for dichotomous vari-
ables. Outcomes were presented as percent 
change (%) and absolute change in hTLV (ml/m) 
and total liver volume (TLV; ml).
For our primary and secondary research questions 
we tested for differences between On-1 versus On-2 
and Off-0 versus Off-1 respectively, using a depend-
ent Student’s t-test for normally distributed data or 
Wilcoxon signed ranks test for nonnormally dis-
tributed data. As it was expected that duration of 
observation periods would follow a skewed distri-
bution, total percent change in hTLV over a total 
period was calculated per 6 months [calculated as: 
((ending value/beginning value) ᶺ (6/duration in 
months) −1) × 100)] to correct for these time dif-
ferences, this being our primary outcome. To ver-
ify these results, we used generalized linear mixed 
models to correct for baseline differences in base-
line hTLV and/or duration of treatment cycle, if 
necessary. A variable ‘patient identifier’ was 
included in our model as random effect to handle 
paired comparisons. Correlation between the 
duration of a drug holiday (Off-1) and the effect in 
Off-1 and On-2 was calculated with a Spearman’s 
correlation coefficient.
We performed a secondary analysis in order to 
determine the response chance after re-exposure 
to SA therapy. Responders were defined as hav-
ing a decrease in hTLV per 6 months (<0% 
growth in hTLV) and nonresponders as having an 
increase in hTLV per 6 months (⩾0% growth in 
hTLV) during the first treatment cycle (On-1).
Subsequently, we performed an exploratory analy-
sis to determine the response rate during the entire 
treatment period (On-1, Off-1, On-2) for the total 
group as well after stratification for responders and 
nonresponders in the first treatment cycle.
Finally, we repeated all analyses in an exploratory 
subgroup analysis by dividing our cohort based on 
disease severity. Patients were classified as mild 
(hTLV < 1600 ml/m), moderate (hTLV 1600–
3200 ml/m), and severe (hTLV > 3200 ml/m).
A p-value of <0.05 was considered significant. 
Analysis were performed using SPSS 22.0 (SPSS 
Inc., Chicago, IL, USA).
Results
Of a total of 231 SA-treated patients, 53 patients 
were re-exposed to SAs during a second treatment 
cycle separated by a drug-free period. Ultimately 
45 patients met our inclusion criteria (Figure 2). 
We included 34 patients for our primary objective, 
11 patients were excluded because imaging (i.e. 
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hTLV) was performed ⩾2 months after start of 
treatment. A total of 25 patients could be included 
for our secondary objective. The main reason for 
exclusion was that no hTLV was available before 
the first treatment cycle (NOT-0 missing, n = 14; 
Figure 1).
Primary objective
Change in hTLV between On-1 and On-2. The 
majority of patients were female (88.2%) and 
diagnosed with ADPKD (61.8%). The mean age 
was nearly 48 years (SD 7.8) at the start of first 
SA treatment (BOT-1; Table 1). The baseline 
liver volume was significantly lower at the start of 
On-1 (BOT-1) compared with On-2 (BOT-2) 
whereas the duration of both treatment cycles 
was similar. In On-1, hTLV decreased with 
−2.6% (IQR −3.8–0.8) per 6 months compared 
with −1.6% (IQR −3.1–1.1) in On-2 which was 
not significantly different [p = 0.510; Table 2 and 
Figure 3(a)]. These findings were confirmed after 
correction for baseline liver volume, treatment 
duration and treatment center using generalized 
linear mixed models (p = 0.253). The absolute 
change in hTLV was similar between On-1 
(−75 ml/m) and On-2 (−70 ml/m, p = 0.263). 
There was a significant correlation between the 
duration of the drug holiday and effect of SAs in 
On-2, with improvement of the liver volume-
reducing effect when longer off treatment 
(r = −0.298, p = 0.016).
There was no difference in serious adverse events 
(SAEs) between On-1 (n = 1; cyst infection) and 
On-2 (n = 2; cyst infection and cyst bleeding). 
No other SAEs were described during SA treat-
ment, such as formation of gall stones or diabetes 
mellitus de novo.
Responders versus nonresponders. In our sec-
ondary analysis, the first treatment with SAs 
resulted in a decrease of hTLV in 22 patients 
(64.7%) whereas in 12 patients, volume reduc-
tion was not achieved (nonresponse). The vast 
majority (86.4%) of responders in On-1 again 
showed a decrease in hTLV after re-exposure to 
SAs (On-2). In case of nonresponsiveness in 
On-1, re-administration of SAs still reduced 
hTLV in 33.3% of patients (Figure 4).
Secondary objective
Change in hTLV between Off-0 and Off-I. Baseline 
characteristics for this subgroup are shown in 
Table S1. hTLV at beginning of each drug-free 
Figure 2. Flowchart of patient selection.
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period (NOT-0 and EOT-1) was not different. 
The observation time was significantly longer in 
Off-1 (18.6 months, IQR 13.9–24.0) compared 
with Off-0 (5.7 months, IQR 5.5–10.0, p = 
0.012; Table 2). The increase in hTLV per 
6 months was significant higher during the drug 
holiday (Off-1) compared with the natural 
growth (Off-0) before pharmaceutical interven-
tion [4.5% versus 1.6%, p = 0.010; Figure 3(b)]. 
After correction for differences in duration using 
generalized linear mixed models, increase in 
hTLV per 6 months remained significant higher 
in Off-1 (p = 0.011), indicating a rebound effect. 
The duration of the drug holiday (Off-1) was 
positively correlated with hTLV growth 
(r = 0.461, p = 0.021).
Response during entire observational period
We determined the response rate during the 
entire observational period (On-1, Off-1, On-2) 
in 34 patients. Patients were treated with SAs 
54.4% of the time and hTLV increased with 0.5% 
per 6 months (4% after 43.5 months). In the 
group of patients who responded in the first treat-
ment cycle (On-1), hTLV decreased with 0.1% 
per 6 months (−0.6% after 46.5 months) whereas 
the livers of nonresponders grew with 1.9% per 
6 months (+14.2% after 40.6 months). 
Nonresponders were treated with SAs relatively 
longer compared with responders (63.7% versus 
53.1%; p = 0.034; Table 3).
Disease severity
We divided patients into two groups based on 
baseline hTLV at the start of the first treatment 
cycle: mild or moderate PLD (18 patients, hTLV 
<3200 ml/m) and severe PLD (16 patients, hTLV 
>3200 ml/m). Both in On-1 and On-2 there was 
no difference in liver volume-reducing effect per 
6 months between the two subgroups. For our 
Table 1. Characteristics of study population (primary objective).
Population (n = 34)
Age at BOT-1 (years) 47.3 ± 7.8
Sex, female (%) 30 (88.2)
hTLV at BOT-1 (in ml/m)¥ 3122.6 (2028.1–4253.3)
 Mild (<1600 ml/m), n (%) 4 (11.8)
 Moderate (1600–3200 ml/m), n (%) 14 (41.2)
 Severe (>3200 ml/m), n (%) 16 (47.1)
Weight (kg) 79.2 ± 11.9
BMI (kg/m2) 27.6 ± 4.2
Treatment center  
 Nijmegen, n (%) 28 (82.4)
 Leuven, n (%) 6 (17.6)
Diagnose  
 ADPKD, n (%) 21 (61.8)
 ADPLD, n (%) 13 (38.2)
Values are shown as mean ± SD (standard deviation) for normally distributed data, median (IQR) for nonnormally 
distributed data or in numbers and percentage (%).
¥Classification mild/moderate/severe based on Kim.24
ADPKD, autosomal dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; BMI, body 
mass index; BOT-1, begin of treatment trial 1; hTLV, height-adjusted total liver volume; IQR, interquartile range.
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secondary objective we observed that semi-annual 
liver growth during drug holiday (Off-1) was sig-
nificantly higher in the severe subgroup (6.2% ver-
sus 2.8%; p = 0.007). The evaluation of liver 
volume change in the entire observational period 
(On-1, Off-1, On-2) was 5.4% (IQR −5.9–23.4) 
per 6 months in the severe group and 1.4% (IQR 
−6.7–12.6) per 6 months in patients with mild/
moderate PLD (p = 0.317; Table S3).
Discussion
In this study we show that PLD patients treated 
with SA-targeted therapy, who discontinue 
treatment, benefit from retreatment at a later 
stage. Patients with an initial good response, 
defined as a decrease in liver volume, are most 
likely to benefit again from SAs during subse-
quent treatment cycles. However, polycystic 
liver growth accelerates after cessation of ther-
apy which complicates the widespread use of a 
drug holiday as a treatment strategy.
A major issue with SAs is that patients tend to 
become tolerant to therapy and lose the maximal 
benefits of medication after 6 months. Indeed, 
open-label studies showed that prolonged 12–
24 months administration of SAs did not demon-
strate beneficial effects in terms of liver volume 
decline as observed in the first months9,25 which 
speaks against the use of continuous therapy. The 
loss of effect beyond 6 months of therapy might be 
explained by desensitization or down-regulation of 
somatostatin receptors (SSTRs). SSTRs are 
expressed on normal and cystic cholangiocytes and 
these receptors are activated by SAs, leading to 
inhibition of cAMP and cell proliferation.4 Several 
animal studies have provided evidence of SSTR 
Table 2. Outcomes of primary (n = 34) and secondary objective (n = 25).
Primary objective On-1 On-2 p-value
n 34 34  
Baseline TLV (ml) 5195 (3261–7443) 5411 (3778–8749) 0.001
Baseline hTLV (ml/m) 3123 (2028–4253) 3371.0 (2319–5211) <0.001
Duration (months) 11.3 (11.0–11.8) 11.4 (6.0–14.5) 0.824
Percent change per 6 months −2.6 (−3.8–0.8) −1.6 (−3.1–1.1) 0.510
Percent change (%) −3.9 (−7.1–1.3) −2.3 (−6.4–2.2) 0.242
Absolute change (ml) – TLV −123 (−412–61) −115 (−318–98) 0.256
Absolute change (ml/m) – hTLV −75 (−243–36) −70 (−193–56) 0.263
Secondary objective Off-0 Off-1 p-value
n 25 25  
Baseline TLV (ml) 5072 (3693–6758) 5051 (3344–6941) 0.459
Baseline hTLV (ml/m) 3160 (2219–3933) 3154 (2104–3914) 0.459
Duration (months) 5.7 (5.5–10.0) 18.6 (13.9–24.0) 0.012
Percent change per 6 months (%) 1.6 (0.2–3.3) 4.5 (1.8–6.4) 0.010
Percent change (%) 2.0 (0.4–3.7) 9.3 (4.4–22.3) 0.001
Absolute change (ml) – TLV 114 (7–212) 382 (219–1026) 0.001
Absolute change (ml/m) – hTLV 68 (4–126) 236 (132–601) 0.001
Values are shown as median (IQR).
p-values were calculated using Wilcoxon signed rank test.
hTLV, height-adjusted total liver volume; IQR, interquartile range; TLV, total liver volume.
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down-regulation after prolonged somatostatin 
treatment (for other diseases), which might explain 
why patients become tolerant with time. 
Confirmation of this hypothesis is needed for PLD 
in human liver cells.26,27 Our study shows that the 
polycystic liver volume-reducing effect of SAs 
repeats after re-exposure, even after an initial treat-
ment cycle of more than 6 months (median 
11.3 months). We hypothesize that the expression 
of SSTR in these patients have been reset during a 
drug holiday. Further studies are needed to clarify 
the role of SAs on SSTRs expression in PLD 
patients during and after therapy.
In our cohort the length of the drug holiday was 
significantly associated with the effect size in terms 
of liver size reduction in the second treatment cycle. 
However, stopping therapy is associated with a 
rebound effect which is correlated with the dura-
tion of drug holiday. This potentially negates the 
beneficial effect of re-exposure. Earlier findings 
from another group reported similar rebound effect 
with liver growth by 9.7% 2 year after SA therapy 
and 4.9% in nontreated patients in a placebo-con-
trolled trial (n = 27).10 They also demonstrated 
that 3 years of treatment with octreotide followed 
by 2 years of follow up resulted in stabilization in 
Figure 3. Primary and secondary outcome. (A) Percentage change in hTLV per 6 months between On-1 
and On-2. (B) Change in hTLV per 6 months between Off-0 and Off-1. Data are presented as a median with 
interquartile range.
hTLV, height-adjusted total liver volume.
Figure 4. Responders versus nonresponders. Response is defined as a decrease in liver volume (<0%). Grey 
boxes represent nonresponders.
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liver volume (−0.8%) despite the rebound effect, 
whereas the livers of patients on placebo increased 
with 11.0% after 5 years. In our study, we saw that 
liver volume increased with 4% in 43.5 months 
after two treatment cycles with an intermittent drug 
holiday (54.4% of the observation time treated) 
with liver volume stabilization (−0.6%) in patients 
who responded to SAs in the first treatment cycle. 
One should realize that the study population of 
Pisani and colleagues10 contained only ADPKD 
patients with mild PLD, whereas our study popula-
tion contains both ADPKD and ADPLD patients 
with moderate/severe PLD with potential more 
liver volume progression. This could explain why 
significant liver reduction has not been detected 
during the treatment cycles. Nonetheless, results of 
both these studies suggest that in a subset of 
patients, treatment with SAs for only half of the 
time could result in overall stabilization of liver vol-
ume, especially for patients that respond well to 
initial SA therapy.
The findings of our subgroup analysis in which 
we divided patients based on PLD severity are 
explorative in nature and should be interpreted 
very carefully due to the low numbers in each 
subgroup. Nonetheless, it suggests that a 
‘rebound effect’ during a drug holiday is more 
severe in patients with severe PLD. This raises 
the hypothesis that patients with mild/moderate 
disease might benefit the most from an intermit-
tent treatment regime. Indeed, in our popula-
tion proportional and absolute liver volume 
change in patients with mild/moderate PLD was 
less increased during the whole observational 
period. Possibly because of the large variety and 
small sample size no significance was detected. 
Further research is needed to confirm this 
hypothesis.
Our present analysis has inherent limitations 
associated with nonprospective studies such as 
variability in patient selection. Most patients 
received SA therapy during a clinical trial or pro-
tocolized standard care, which enabled collec-
tion of high quality data. The main reason for 
re-exposure to SAs was that patients participated 
in a second clinical trial. It is likely that patients 
who did not tolerate SAs during first exposure, 
were not willing to proceed to the subsequent 
Table 3. Baseline characteristics stratified for responders and nonresponders.
Total Responders Nonresponders p-
value
n 34 22 12  
Sex, female (%) 30 (88.2) 19 (86.4) 11 (91.7) 0.556
Age at BOT-1 (years) 46.5 (41.8–51.3) 47.0 (42.0–53.3) 45.5 (40.0–47.8) 0.292
Diagnosis ADPLD/ADPKD (n) 13/21 11/11 2/10 0.059
hTLV at BOT-1 (ml/m) 3122.6 (2028.1–4253.3) 2860.1 (2124.4–4444.2) 3576.0 (2075.8–4228.1) 0.683
Duration of total observation period1 
(months)
43.5 (38.2–48.6) 46.5 (41.1–49.2) 40.6 (22.2–44.2) 0.013
Percentage change per 6 months BOT-1 
versus EOT-2 (%)
0.5 (−0.8–2.2) −0.1 (−1.1–0.9) 1.9 (1.2–3.6) 0.001
Percentage change BOT-1 versus EOT-2 
(%)
4.0 (−6.5–16.9) −0.6 (−7.4–5.7) 14.2 (5.0–28.4) 0.001
Percentage of time treated in total 
observation period (%)
54.4 (47.8–65.4) 53.1 (41.1–60.0) 63.7 (52.1–79.0) 0.034
Values are shown in absolute numbers (%) or median (IQR).
p-values are calculated between responders and nonresponders using Chi-square tests (absolute data) or independent-samples Mann–Whitney U 
test (continuous data). p < 0.05.
1Total observation period consists of On-1 + Off-1 + On-2.
ADPKD, autosomal dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; BOT1, begin of treatment trial 1;  
EOT-2, end of trial 2; hTLV, height-adjusted total liver volume; IQR, interquartile range.
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trial. Although this might lead to selection bias, 
it corresponds with daily practice as nontolera-
ble patients will not be treated. Furthermore, we 
were able to include both responders and nonre-
sponders to SAs in our study which reduces 
potential selection bias. Secondly, the sample 
size of this cohort is small because of the rarity of 
PLD and the low frequency of SA prescription. 
Treatment with SAs in PLD has only been avail-
able for a couple of years which complicates 
obtaining a larger cohort that meets our inclu-
sion criteria. Nonetheless, all patients from the 
International PLD Registry were screened and 
included when eligible. Third, we could not 
explore the effect of dosage, type of drug and 
etiology on our primary outcome because of lack 
of power. No studies directly compared the effi-
cacy between octreotide and lanreotide, however 
multiple trials demonstrated comparable results 
for both types of SA.5 The results in both treat-
ment cycles seen on SAs in this study are in line 
with these trials. In a pooled analysis of four tri-
als including treatment with lanreotide 120 mg 
or octreotide 40 mg for 6–12 months, SA type 
and underlying diagnose did not significantly 
interact with treatment effect.28 One clinical trial 
explored alternative doses of lanreotide and 
found that both 90 mg and 120 mg reduce liver 
volume compared with placebo with numerically 
higher effect when exposed to 120 mg.18 In the 
second treatment cycle of our study, five patients 
were treated with lanreotide 90 mg of which 
three patients had a dose escalation to 120 mg 
because of nonresponse after 6 months. In the 
first treatment cycle only one patient was treated 
with lanreotide 90 mg (with dose escalation to 
120 mg). It is possible that a lower dosage 
masked the effect of treatment leading to under-
estimation of the liver volume-reducing effect of 
SAs in On-2 (Table S2).
A strength of our study is that independent assess-
ment of liver size measurements was part of the 
treatment protocol. Although different quantifi-
cation methods were used to measure liver vol-
ume, all of these methods are frequently used in 
trials and standard of care. Previous studies 
showed that the agreement between techniques 
and inter-observer variability is low which mini-
mizes its potential effect on our results.6,18,21 
Patients did not receive other treatment that may 
have affected the primary outcome of the study 
and as such the study results may be ascribed to 
the effect of SAs therapy.
The findings of this study are a prelude to further 
exploration of alternative SA treatment strategies 
and contribute to a better understanding of the 
pharmacological effect of SAs in PLD. Although 
the effect of SA therapy is reproducible, the 
rebound effect after cessation of treatment com-
plicates the implementation of drug holidays. Our 
data fuel the evidence base for alternative 
approaches for physicians who might be anxious 
to discontinue therapy. For instance, it could be 
worthwhile to discontinue SA therapy in patients 
who become asymptomatic under treatment or 
for those who have a lower risk for significant liver 
growth (e.g. women who entered the meno-
pause). Liver growth rate can be followed, and, in 
the case of accelerated liver growth, treatment 
can be resumed safely with high probability of 
response. This low-risk strategy potentially avoids 
needless continuous therapy (with possible loss of 
effect) and reduces medical costs. Second, these 
results afford a more granular picture of the effect 
after cessation or re-exposure to SAs. Third, in a 
subset of patients, intermittent treatment might 
be a potential strategy as it may lead to an overall 
stabilization of liver volume. Future research is 
needed to explore the effect of intermittent treat-
ment on liver volume and symptoms and to iden-
tify those who might benefit from this regimen.
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